1530 (1530) News
Follow 1530 (1530) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Awea Mechantronic reports Sep quarter revenue of NT$295.8M
Awea Mechantronic Co. Ltd. reported September-quarter revenue of NT$295.8M versus NT$80.5M a year earlier. Jan-Sep revenue was NT$1,534,487,000 versus NT$1,456,551,000 in 2025.
EQUITY | Oct 08, 2026, 06:12 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Awea Mechantronic reports Aug revenue NT$87.4M vs NT$153.2M
Awea Mechantronic Co. Ltd. reported August revenue of NT$87,383,000, versus NT$153,168,000 in the prior year. It also reported Jan-Aug revenue of NT$1,238,669,000 versus NT$1,376,040,000, per Taiwan Stock Exchange data.
EQUITY | Sep 10, 2026, 06:19 AM UTC